The world in which Inosan Biopharma was created presented a challenge: many pharmaceutical companies, choosing to focus on more profitable product lines, were in the process of, or had completely abandoned, the business of antivenoms. Infamously difficult to produce, especially at scale, antivenoms were increasingly becoming a neglected industry.
Yet the global need for antivenoms was growing, not shrinking, and people were increasingly vulnerable, across the world, to injury and death from animal envenomation. This was placing a burden on families, organizations and governments in the affected regions. …
Durante el Segundo Congreso Nacional de Vipéridos Mexicanos y Ofidismo en Aguascalientes, México, en mayo de 2019, el Dr. Luis Eduardo Robles Ortíz por parte de Inosan Biopharma, estuvo encargado de dar una conferencia magistral sobre los aspectos clínicos del accidente ofídico.
Esta plática tocó varios puntos, pero tomando en cuenta que la audiencia en el congreso estaba principalmente formada por biólogos, herpetólogos e investigadores.
“El éxito de la atención clínica depende mucho de lo que se haga en la atención prehospitalaria”
NO HACER:
To stop anyone from suffering or dying as a consequence of animal envenomation